Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary (1983)
    Springer
    Investigational new drugs 1 (1983), S. 185-188 
    Details
    ISSN: 1573-0646
    Keywords: ovarian carcinoma ; Baker's antifol ; triazinate ; Phase II study
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Twenty-nine patients with advanced ovarian carcinoma were entered into a Gynecologic Group Phase II study of Baker's Antifol. Of these, 26 were eligible for evaluation of toxicity and 25 for evaluation of response. The evaluable patients constituted an unusually favorable group for a Phase II study in a chemotherapy-sensitive tumor; although all have received prior chemotherapy, eight had had treatment with only a single alkylating agent and the median performance status of the study population was two (ambulatory, capable of self-care). No complete responses were seen. Two patients had regression of abdominal tumor masses sufficient to qualify as partial responders (PR 8%). Dose-limiting toxicity, as expected, was found to be gastrointestinal. Significant mucositis and dermatitis were also observed. No episodes of hypotension during infusion occurred with a 60–120 min time of administration. Baker's antifol has only limited activity against ovarian carcinoma previously treated with chemotherapy and is not likely to contribute to improved therapy, either as a single agent or in combination.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00172079
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma (1983)
    Springer
    Investigational new drugs 1 (1983), S. 239-242 
    Details
    ISSN: 1573-0646
    Keywords: bruceantin ; Phase II study ; melanoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The Eastern Cooperative Oncology Group (ECOG) conducted a Phase II trial of Bruceantin in malignant melanoma. Twenty-two patients, thirteen without prior cytotoxic chemotherapy, were entered. All patients were evaluable for response and toxicity. Dose limiting toxicity was found to be hypotension during Bruceantin infusion. Other prominent side effects were nausea, vomiting, anorexia, fever, chills, and weakness. Only minor hematologic toxicity was encountered. Two partial responses, both in previously treated patients were observed (response rate — 9%). Bruceantin has only limited activity against malignant melanoma and is unlikely to contribute to systemic therapy of this disease, either as a single agent or in combinations of cytotoxic drugs.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00208896
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...